Insitro Company
Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics. In 2018, Daphne Koller established Insitro in South San Francisco, California..
Investors
.png)
.png)
.png)
.jpeg)
.png)
.png)
(Reupload).png)
.jpg)
.png)
.png)
(Reupload).png)
.png)
(Reupload).png)
.jpeg)
.png)
.jpeg)
.png)
(Reupload).png)
Technology:
Biotechnology, Life Science, Machine Learning, Pharmaceutical, Therapeutics
Industry:
Early Drug Development
Headquarters:
South San Francisco, California, United States
Founded Date:
2018-01-01
Employees Number:
101-250
Funding Status:
Late Stage Venture
Acquisitions Number:
1
Investors Number:
19
Total Funding:
743000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2021-03-15
Last Funding Type:
Series C
Register and Claim Ownership